SAN FRANCISCO (EGMN) - Men with prostate cancer who are on active surveillance may be overtreated if their clinicians rely strictly on certain commonly used prostate-specific antigen triggers for starting treatment, Dr. Andrew Loblaw told attendees of a symposium on genitourinary cancers. In a cohort of 315 such men who had no evidence of disease progression, the percentage in whom treatment would have been falsely triggered ranged widely - from 14% to 84% - depending on which of nine PSA measures...